Vorinostat (rINN) also known as suberanilohydroxamic acid is a member of a larger class of compounds that inhibit histone deacetylases (HDAC).
Drug information on Vorinostat for patients and consumers.
Vorinostat is a synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic ...
Vorinostat (Zolinza) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatment of cutaneous T-cell lymphoma.
Jul 3, 2013 ... On October 6, 2006, the U.S. Food and Drug Administration granted approval to vorinostat (Zolinza™, Merck & Co., Inc.), a histone deacetylase ...
Jun 13, 2005 ... Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar ...
Vorinostat also known as SAHA, Zolinza, MK-0683 is an HDAC inhibitor. Vorinostat CAS No 149647-78-9 with purity >99% & solubility DMSO is available.
Vorinostat (Zolinza; Merck) was approved by the US FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell ...
Results of animal studies indicate that vorinostat crosses the placenta and is found in fetal plasma at levels up to 50% of maternal concentrations. Doses.